New agents for Type 2 diabetes

Bailliere's Best Practice and Research in Clinical Endocrinology and Metabolism

Volumn 13, Issue 2, 1999, Pages 309-329

  Nattrass, Malcolm ^a   Bailey, Clifford J ^b  

^a SELLY OAK HOSPITAL   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

Acarbose; Anti diabetic drugs; Insulin resistance; Metformin; Sulphonylureas; Thiazolidinediones

Indexed keywords

ACARBOSE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDIABETIC AGENT; CARBOHYDRATE; ENZYME INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LIPASE INHIBITOR; METFORMIN; MITIGLINIDE; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN; TROGLITAZONE; UNCLASSIFIED DRUG;

BLOOD GLUCOSE MONITORING; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; DIABETIC OBESITY; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; GENETIC TRANSCRIPTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LIPID METABOLISM; LIVER TOXICITY; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOGENESIS; POSTPRANDIAL STATE; REVIEW; WEIGHT REDUCTION;

EID: 0033502306     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1053/beem.1999.0023     Document Type: Article

References (73)

1. Temple R C, Carrington C A, Luzio S D. Insulin deficiency in non-insulin-dependent diabetes. Lancet. 1:1989;293-295.
2. Williams D RR, Byrne C, Clark P MS. Raised proinsulin concentration as an early indicator of B cell dysfunction. British Medical Journal. 303:1991;95-96.
3. Porte D, Pupo A A. Insulin responses to glucose: evidence for a two pool system in man. Journal of Clinical Investigation. 48:1969;2309-2319.
4. Clark A, Brown E, King T. Islet changes induced by hyperglycemia in rats: effect of insulin or chlorpropamide therapy. Diabetes. 31:1982;319-325.
5. Cheatham B, Kahn C R. Insulin action and the insulin signalling network. Endocrine Reviews. 16:1995;117-142.
6. Himsworth H P. Diabetes mellitus; its differentiation into insulin-sensitive and insulin-insensitive types. Lancet. 1:1936;127-130.
7. Reaven G M. Pathophysiology of insulin resistance in human disease. Physiological Reviews. 75:1995;473-486.
8. Randle P J, Garland P B, Hales C N, Newsholme E A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes. Lancet. 1:1963;785-789.
9. Lancet. 352:1998;837-853.
10. Panzram G. Mortality and survival in type 2 (non-insulin dependent) diabetes mellitus. Diabetologia. 30:1987;123-131.
11. Hanefield M, Fischer S, Julius U. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11 year follow-up. Diabetologia. 39:1996;1577-1583.
12. Diabetes. 44:1995;1249-1258.
13. Dills D G, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind study. Hormone and Metabolic Research. 28:1996;426-429.
14. Langtry H D, Balfour J A. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs. 55:1998;563-584.
15. Bijlstra P J, Lutterman J A, Russel F GM. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia. 39:1996;1983-1090.
16. Graul A, Castaner J. Repaglinide. Drugs of the Future. 21:1996;694-699.
17. Malaisse W J. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Hormone Metabolism Research. 27:1995;263-266.
18. Fuhlendorff J, Rorsman P, Kofod H. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes. 47:1998;345-351.
19. Wolffenbuttel B HR, Nijst L, Sels J P. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. European Journal of Clinical Pharmacology. 45:1993;113-116.
20. Lehmann J M, Moore L B, Smith-Oliver T A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). Journal of Biological Chemistry. 270:1995;12593-12596.
21. Spiegelman B M. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes. 47:1998;507-514.
22. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Medicine. 16:1999;1-14.
23. Maggs D G, Buchanan T A, Burant C F. Metabolic effects of troglitazone on monotherapy in type 2 diabetes mellitus. Annals of Internal Medicine. 128:1998;176-185.
24. Kumar S, Boulton A JM, Beck-Nielsen H. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia. 39:1996;701-709.
25. Inzucchi S E, Maggs D G, Spollett G R. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. New England Journal of Medicine. 338:1998;867-872.
26. Ghazzi M N, Perez J E, Antonucci T K. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes. 46:1997;433-439.
27. Watkins P B, Whitcomb R W. Hepatic dysfunction associated with troglitazone. New England Journal of Medicine. 338:1998;916-917.
28. Seed B. PPARγ and colorectal carcinoma: conflicts in a nuclear family. Nature Medicine. 4:1998;1004-1005.
29. Wing R R, Shoemaker M, Marcus M DM. Variables associated with weight loss and improvements in glycaemic control in type 2 diabetic patients. Archives of Internal Medicine. 147:1990;1749-1753.
30. McNeely W, Benfield P. Orlistat. Drugs. 56:1998;241-249.
31. Sjostrom L, Rissanen A, Anderson T. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 352:1998;167-172.
32. Hollander P A, Kaplan R A, Elbein S C. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 21:1998;1288-1294.
33. Jackson H C, Bearham M C, Hutchins L J. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. British Journal of Pharmacology. 121:1997;1613-1618.
34. Connoley I P, Heal D J, Stock M J. A study in rats of the effects of sibutramine on food intake and thermogenesis. British Journal of Pharmacology. 114:1995;388P.
35. Weintraub M, Rubio A, Goli A. Sibutramine in weight control: a dose-ranging, efficacy study. Clinical Pharmacology and Therapeutics. 50:1991;330-337.
36. Griffiths J, Byrnes A E, Frost G. Sibutramine in the treatment of overweight non-insulin dependent diabetics. International Journal of Obesity. 19:1995;41.
37. Bailey C J. Insulin resistance and antidiabetic drugs. Biochemical Pharmacology. 58:1999.
38. DeFronzo R A. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 37:1988;667-687.
39. Porte D. β-cells in type II diabetes mellitus. Diabetes. 40:1991;166-180.
40. Bailey C J, Williams G, Pickup J C. New drugs in the management of diabetes mellitus and its complications. Pickup J C, Williams G. Textbook of Diabetes. 1997;84.1-84.30 Blackwell, Oxford.
41. Bailey C J. New drugs for the treatment of diabetes mellitus. Alberti K GMM, DeFronzo R A, Zimmet P, Keen H. International Textbook of Diabetes Mellitus. 1997;865-881 John Wiley & Sons, Chichester.
42. Bailey C J. New pharmacological approaches to glycemic control. Diabetes Reviews. 7:1999;94-113.
43. Akiyoshi M, Kakei M, Nakazaki M, Tanaka H. A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic β-cells. American Journal of Physiology. 268:1995;E185-E193.
44. Kinukawa M, Ohnota H, Ajisawa Y. Effect of a non-sulphonylurea hypoglycaemic agent, KAD-1229 on hormone secretion in the isolated perfused pancreas of the rat. British Journal of Pharmacology. 117:1996;1702-1706.
45. Page T, Bailey C J. Blood glucose-lowering effect of morpholinoguanidine derivative BTS 67 582. British Journal of Pharmacology. 122:1997;1464-1468.
46. Bjorking F, Malaisse-Lagae F, Malaisse W J. Insulinotropic action of novel succinic acid esters. Pharmacology Research. 33:1996;273-275.
47. Nauck M A. Glucagon-like peptide 1. Current Opinion in Endocrinology and Diabetes. 4:1997;291-299.
48. Drucker D J. Glucagon-like peptides. Diabetes. 47:1998;159-169.
49. Pederson R A, White H A, Schlenzig D. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolide. Diabetes. 47:1998;1253-1258.
50. Leibowitz M D, Biswas C, Brady E J. A novel insulin secretagogue is a phosphodiesterase inhibitor. Diabetes. 44:1995;67-74.
51. Stevenson R W, Gibbs E M, Kreutter D K. The thiazolidinedione drug series. Diabetes Annual. 9:1995;175-191.
52. Young P W, Cawthorne M A, Coyle P. Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes. Diabetes. 44:1995;1087-1092.
53. Hallakou S, Foufelle F, Doare L. Pioglitazone-induced increase of insulin sensitivity in the muscles of the obese Zucker fa/fa rat cannot be explained by local adipocyte differentiation. Diabetologia. 41:1998;963-968.
54. Shibata T, Matsui K, Yonemori F. JTT-501, a novel oral antidiabetic agent, improves insulin resistance in genetic and non-genetic insulin resistant models. British Journal of Pharmacology. 125:1998;1744-1750.
55. Cohen N, Halberstam M, Stilimovich P. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus in vivo and in vitro studies. Journal of Clinical Investigation. 95:1995;2501-2509.
56. Goldfine A B, Simonson S C, Folli F. Metabolic effects of sodium metabanadate in humans with insulin-dependent and non-insulin-dependent diabetes mellitus in vivo and in vitro studies. Journal of Clinical Endocrinology and Metabolism. 80:1995;33111-33120.
57. Posner B I, Fraure R, Burgress J W. Peroxovandium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. Journal of Biological Chemistry. 269:1994;4596-4604.
58. Anderson R A, Cheng N, Bryden N A. Elevated intakes of supplemental chronium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes. 46:1997;1786-1791.
59. Moses A C, Young S CJ, Morrow L A. Recombinant human insulin-like growth factor 1 increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes. 45:1996;91-100.
60. Lebovitz H. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Reviews. 6:1998;132-145.
61. Johnston P S, Santiago J V, Confiff R F. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care. 17:1994;20-29.
62. Goke B, Fuder H, Wieckhorst G. Voglibose (AO-128) is an efficient α-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion. 56:1995;493-501.
63. Jeffcoate S, Organ K, Schoenfeld S. Efficacy and safety of subcutaneous pramlintide therapy in people with type 2 diabetes. Diabetic Medicine. 15:1998;S5.
64. Fulcher G R, Walker M, Farrer M. Acipimox increases glucose disposal in normal man independent of changes in plasma non-esterified fatty acid concentration and whole body lipid oxidation. Metabolism. 42:1993;308-314.
65. Jones I R, Swai A, Taylor R. Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care. 13:1990;855-863.
66. Bianchi R, Bohgers V, Bravenboer B, Erkelens D W. Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. Diabetes Care. 16:1993;557-559.
67. Frenkel B, Bishara-Shieban J, Bar-Tana J. The effect of β,β-methyl-substituted hexadecanedioic acid on plasma VLDL metabolism in rats: role of adolipoprotein C-III. Biochemical Journal. 298:1994;409-414.
68. Foley J E. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus. Diabetes Care. 15:1992;773-784.
69. 3-adrenoceptor agonist in humans. Diabetes. 47:1998;1555-1561.
70. Unson C G, MacDonald D, Ray K. Position 9 replacement analogs of glucagon uncouple biological activity and receptor binding. Journal of Biological Chemistry. 266:1991;2763-2766.
71. Stacpole P W, Greene Y K. Dichloroacetate. Diabetes Care. 15:1992;785-791.
72. Vincent M F, Erion M D, Gruber H E. Hypoglycaemic effect of AIC Ariboside in mice. Diabetologia. 39:1996;1148-1155.
73. Parker J C, VanVolkenburg M A, Levy C B. Plasma glucose levels are reduced in rats and mice treated with an inhibitor of glucose-6-phosphate translocase. Diabetes. 47:1998;1630-1636.